Literature DB >> 29269016

Functional changes in vascular reactivity to adenosine receptor activation in type I diabetic mice.

Hicham Labazi1, Bunyen Teng2, S Jamal Mustafa3.   

Abstract

Activation of adenosine receptors has been implicated in several biological functions, including cardiovascular and renal function. Diabetes causes morphological and functional changes in the vasculature, resulting in abnormal responses to various stimuli. Recent studies have suggested that adenosine receptor expression and signaling are altered in disease states such as hypertension, diabetes. Using a streptozotocin (STZ) mouse model of type I diabetes (T1D), we investigated the functional changes in aorta and resistance mesenteric arteries to adenosine receptor agonist activation in T1D. Organ baths and DMT wire myographs were used for muscle tension measurements in isolated vascular rings, and western blotting was used for protein analysis. Concentration response curves to selective adenosine receptor agonists, including CCPA (A1 receptor agonist), Cl-IBMECA (A3 receptor agonist), CGS-21680 (A2A receptor agonist), and BAY 60-6583 (A2B receptor agonist), were performed. We found that diabetes did not affect adenosine receptor agonist-mediated relaxation or contraction in mesenteric arteries. However, aortas from diabetic mice exhibited a significant decrease (P < 0.05) in A1 receptor-mediated vasoconstriction. In addition, the aortas from STZ-treated mice exhibited an increase in phenylephrine-mediated contraction (EC50 7.40 ± 0.08 in STZ vs 6.89 ± 0.14 in vehicle; P < 0.05), while relaxation to A2A receptor agonists (CGS-21680) tended to decrease in aortas from the STZ-treated group (not statistically significant). Our data suggest that changes in adenosine receptor(s) vascular reactivity in T1D is tissue specific, and the decrease in A1 receptor-mediated aortic contraction could be a compensatory mechanism to counterbalance the increased adrenergic vascular contractility observed in aortas from diabetic mice.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenosine; Adenosine receptors; Diabetes; Vascular function

Mesh:

Substances:

Year:  2017        PMID: 29269016      PMCID: PMC5767150          DOI: 10.1016/j.ejphar.2017.12.034

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  46 in total

Review 1.  Role of adenosine signaling in penile erection and erectile disorders.

Authors:  Prasad V Phatarpekar; Jiaming Wen; Yang Xia
Journal:  J Sex Med       Date:  2010-11       Impact factor: 3.802

2.  Modification of adenosine A1 and A2A receptor density in the hippocampus of streptozotocin-induced diabetic rats.

Authors:  João M N Duarte; Catarina R Oliveira; António F Ambrósio; Rodrigo A Cunha
Journal:  Neurochem Int       Date:  2005-10-26       Impact factor: 3.921

3.  NADPH oxidase pathway is involved in aortic contraction induced by A3 adenosine receptor in mice.

Authors:  Mohammed S El-Awady; Habib R Ansari; Daniel Fil; Stephen L Tilley; S Jamal Mustafa
Journal:  J Pharmacol Exp Ther       Date:  2011-05-23       Impact factor: 4.030

4.  Streptozotocin-induced diabetic models in mice and rats.

Authors:  Kenneth K Wu; Youming Huan
Journal:  Curr Protoc Pharmacol       Date:  2008-03

5.  Stimulation of A(2A) adenosine receptor phosphorylation by protein kinase C activation: evidence for regulation by multiple protein kinase C isoforms.

Authors:  T M Palmer; G L Stiles
Journal:  Biochemistry       Date:  1999-11-09       Impact factor: 3.162

Review 6.  Signalling from adenosine receptors to mitogen-activated protein kinases.

Authors:  Gunnar Schulte; Bertil B Fredholm
Journal:  Cell Signal       Date:  2003-09       Impact factor: 4.315

7.  Role of calcium-independent phospholipase A2beta in high glucose-induced activation of RhoA, Rho kinase, and CPI-17 in cultured vascular smooth muscle cells and vascular smooth muscle hypercontractility in diabetic animals.

Authors:  Zhongwen Xie; Ming C Gong; Wen Su; Dongping Xie; John Turk; Zhenheng Guo
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

8.  Enhanced A2A adenosine receptor-mediated increase in coronary flow in type I diabetic mice.

Authors:  Hicham Labazi; Bunyen Teng; Zhichao Zhou; S Jamal Mustafa
Journal:  J Mol Cell Cardiol       Date:  2015-12-02       Impact factor: 5.000

9.  Diabetes-induced alterations of adenosine receptors expression level in rat liver.

Authors:  Marzena Grden; Marzena Podgorska; Andrzej Szutowicz; Tadeusz Pawelczyk
Journal:  Exp Mol Pathol       Date:  2007-04-04       Impact factor: 3.362

10.  Altered mechanism of adenosine-induced coronary arteriolar dilation in early-stage metabolic syndrome.

Authors:  Shawn B Bender; Johnathan D Tune; Lena Borbouse; Xin Long; Michael Sturek; M Harold Laughlin
Journal:  Exp Biol Med (Maywood)       Date:  2009-03-23
View more
  6 in total

1.  Alkaline Phosphatase Activity Is a Key Determinant of Vascular Responsiveness to Norepinephrine.

Authors:  Edwin K Jackson; Dongmei Cheng; Vladimir B Ritov; Zaichuan Mi
Journal:  Hypertension       Date:  2020-08-24       Impact factor: 10.190

Review 2.  Alteration of purinergic signaling in diabetes: Focus on vascular function.

Authors:  Rui Zhou; Xitong Dang; Randy S Sprague; S Jamal Mustafa; Zhichao Zhou
Journal:  J Mol Cell Cardiol       Date:  2020-02-11       Impact factor: 5.000

Review 3.  Purinergic Signaling During Hyperglycemia in Vascular Smooth Muscle Cells.

Authors:  Miguel Martin-Aragon Baudel; Ricardo Espinosa-Tanguma; Madeline Nieves-Cintron; Manuel F Navedo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-22       Impact factor: 5.555

Review 4.  Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes.

Authors:  Olakunle Sanni; G Terre'Blanche
Journal:  Rev Endocr Metab Disord       Date:  2021-06-24       Impact factor: 6.514

Review 5.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

Review 6.  Purinergic Signalling in Parkinson's Disease: A Multi-target System to Combat Neurodegeneration.

Authors:  Adrián Tóth; Zsófia Antal; Dániel Bereczki; Beáta Sperlágh
Journal:  Neurochem Res       Date:  2019-05-04       Impact factor: 3.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.